Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06958536 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

Study acronym: CHROMA CD
StatusRecruiting
PhasePhase 2
SponsorSanofi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Interventions modified Show 4 more changesShow less
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: 18 to 13
    • Site details revised at 2 of 66 sites
    • Study title revised
  2. Study sites: 60 to 66v15
  3. Study sites: 56 to 60v14
  4. Study sites: 50 to 56v13
  5. Eligibility criteria revised
    • Secondary endpoints: details revised at 14 of 18 entries
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 46 to 50v11
  2. Study sites: 33 to 46v10
  3. Study sites: 26 to 33v9
  4. Study sites: 13 to 26v8
  5. Study sites: 10 to 13v7
  6. Re-verified, no change to tracked fieldsv6
  7. Study sites: 9 to 10v5
  8. Study sites: 8 to 9v4
  9. Study sites: 6 to 8v3
  10. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sanofi
284 trials monitored
See 12 trials at risk
Crohn's Disease
642 trials monitored
See 34 trials at risk
This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Trial Details
NCT Number NCT06958536
Lead Sponsor Sanofi
Conditions
(from sponsor)		 Crohn's Disease
Related terms Crohn Disease
Enrollment 99 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov